Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
This article was originally published in The Pink Sheet Daily
Allergan PLC's generic version of AstraZeneca PLC's blockbuster statin Crestor (rosuvastatin) is likely to need only a few weeks on the US market to surpass total sales of the PCSK9 inhibitors to date.
You may also be interested in...
Company is waging the same legal battle Otsuka lost last year, arguing pediatric orphan indication should block approvals of ANDAs.
First in class is the first to fall, and Byetta could go even earlier than the October 2017 date set in Teva settlement since AstraZeneca still faces a generic challenge from Amneal – and a direct attack on its patents from Sanofi.
UnitedHealth will drop AstraZeneca's brand from coverage after competition drives down price of generic rosuvastatin.